Citations

Clear

3030 citation(s) found for "Susan, M".

Window of opportunity evaluation of blood–brain barrier permeability heterogeneity within and across high-grade glioma patients
Oh, Ju‐Hee , Reed, Sarah K, Riviere-Cazaux, Cécile , Mladek, Ann C. , Caron, Alissa, Mohammad, Afroz S., Hu, Leland , Kizilbash, Sani H. , Geyer, Susan, Elmquist, William F. , Sarkaria, Jann N. , Dixon, Jesse G. , Kaufmann, Timothy J , Kizilbash, Sani, Giannini, Caterina , Galanis, Evanthia , Sarkaria, Jann N , Kizilbash, Sani H , Mladek, Ann C , Reed, Sarah K, Kim, Minjee , Illamola, Sílvia M. , Zhang, Wenjuan , Vaubel, Rachael A. , Regan, Michael S. , Birnbaum, Angela K. , Zhang, Wenqiu , Kaufmann, Timothy J. , Daniel, J. , Agar, Nathalie Y.R. , Giannini, Caterina , Parney, Ian F. , Galanis, Evanthia , Burns, Terry C.

Mayo Clinic

Neuro-Oncology | September 3, 2025 | Volume: 28 | Issue: 1 | Pages: 130-142

10.1093/neuonc/noaf204 | PMID 40916832 Get It

Abstract Background Disruption of the blood–brain barrier (BBB) in high-grade brain tumors is characterized by contrast accumulation on diagnostic imaging. This window of opportunity study correlates contrast imaging features with the tumor distribution of BBB-permeable (levetiracetam) and -impermeable (cefazolin) drugs. Methods Patients with a clinical diagnosis of a high-grade brain tumor underwent MRI for surgical planning. Cefazolin and levetiracetam were administered prior to skin incision, and serial plasma and image-registered tumor samples were collected during the operation. Drug levels were measured by LC-MS/MS, tissue drug levels were corrected for residual blood, and tumor-to-plasma concentration ratios were calculated. Intraoperative microdialysis was performed in a subset of patients to measure the same two drugs. Results Tumor (n = 125) and plasma (n = 261) samples were available for analysis from 42 operative cases. Across all samples, the tumor-to-plasma ratio was significantly lower for cefazolin (marginal mean [MM]: 0.15, 95% CI: 0.11–0.19) as compared to levetiracetam (MM: 0.70, 95% CI: 0.64–0.75; P < .001). When compared between contrast-enhancing and non-enhancing regions, tumor-to-plasma ratios for cefazolin varied by 4.4-fold (0.27, 95% CI: 0.20–0.35 vs. 0.06, 95% CI: 0.04–0.08, respectively; P < .001), and varied for levetiracetam by 1.4-fold (0.88, 95% CI: 0.78–0.97 vs. 0.61, 95% CI: 0.55–0.66, respectively; P < .001). These results were confirmed with the intra-operative microdialysis and a population pharmacokinetic analysis. Conclusions This study demonstrates significant inter- and intra-tumoral heterogeneity in drug delivery for both levetiracetam and cefazolin within high-grade brain tumors that is not necessarily predicted by clinical MR imaging and may reflect tumor-induced changes in both perfusion and BBB integrity.
Enhancing Margin Precision: A Work System Approach to Lumpectomies and Mastectomies
Nadri, Chihab , Skurnak, Kaitlin , Zoaktafi, Mojgan, Bourgeois, Gavin , Norasi, Hamid , Wooldridge, Abigail R. , Hallbeck, M. Susan

Mayo Clinic

Proceedings of the Human Factors and Ergonomics Society Annual Meeting | September 1, 2025 | Volume: 69 | Issue: 1 | Pages: 447-449

10.1177/10711813251369400 Get It

Achieving negative surgical margins is critical for patient outcomes in breast-conserving surgery (BCS), however positive margins require reoperation in 20% to 40% of cases currently. This study explores design criteria and current barriers and facilitators to margin definition and assessment as part of designing an intraoperative tool for margin assessment during BCS. We conducted observations of nine surgeries by four surgeons at a quaternary medical center. We analyzed the data using the Systems Engineering Initiative for Patient Safety (SEIPS) model to identify barriers and facilitators to margin assessment. We identified 38 barriers and 62 facilitators, which we inductively categorized into dimensions. The dimensions included teamwork, information display design, intraoperative tool use, and tissue characteristics. Teamwork was the most frequently observed dimension, followed by information display design and intraoperative tool use. This study provides insights to support the design of workflow-adaptive solutions and improve margin accuracy and surgical performance in breast oncology procedures.
European‐based polygenic risk score and genome‐wide association study of B‐cell non‐Hodgkin lymphoma subtypes in Israeli Jews and Palestinian Arabs
Kleinstern, Geffen , Robinson, Dennis P. , Perlman, Riki , Jebrini, Nidal, Elyan, Hussein, Yehuda, Dina Ben , Paltiel, Ora , Paltiel, Ora , Seir, Rania Abu , Liu, Jianjun , Elyan, Hussein, Slager, Susan L.

Mayo Clinic

British Journal of Haematology | August 31, 2025 | Volume: 207 | Issue: 5 | Pages: 1832-1841

10.1111/bjh.70125 | PMID 40887045 Get It

Summary Among individuals of European Ancestry (EA), genome‐wide association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) and polygenic risk scores (PRSs) associated with non‐Hodgkin lymphoma (NHL) risk. We evaluated subtype‐specific PRSs, based on established EA‐SNPs, in Israeli Jews (IJ) and Palestinian Arabs (PA) and performed a GWAS in the combined ethnic groups to identify new loci. We included three common pathologically confirmed subtypes: diffuse large B‐cell (DLBCL), follicular (FL) and marginal zone (MZL) lymphomas. Controls were frequency matched to cases by age and sex. Among 752 IJ (201—DLBCL; 130—FL; 54—MZL/367—controls) and 593 PA (203—DLBCL; 41—FL/349‐controls), we computed PRSs weighted by EA‐derived effect estimates and used logistic regression models adjusted for confounders. In the combined ethnic groups of IJ and PA, subtype‐specific PRSs were significantly associated with the corresponding subtype, with a 1.69‐fold, 2.21‐fold and 2.26‐fold risk for DLBCL, FL and MZL, respectively; however, these effect sizes were attenuated compared to those reported in EA and varied by ethnicity. In the GWAS of the combined ethnic groups, two novel SNPs in the 6p21.32 locus were associated with DLBCL risk. Additional GWAS studies are needed among Jewish and Arab populations to improve genetic risk prediction for NHL in these ethnic groups.
Participation of Women in Cardiovascular Trials From 2017 to 2023
Magalong, John Vincent , Bantayan, Nathan Ross B. , Tesoro, Nicole Ann , Milan, Mark Jason, Purewal, Vikramjit , Pine, Polyn Luz S, Lala-Trindade, Anuradha, Cheng, Susan, Gulati, Martha , Rivera, Frederick Berro , Tsai, Chieh-Mei , Lara-Breitinger, Kyla , Milan, Mark Jason D. C. , Návar, Ann Marie , Mulvagh, Sharon L. , Januzzi, James L. , Gibson, C. Michael , Cheng, Susan, Lara-Breitinger, Kyla M , Guerrero, Mayra

Mayo Clinic

JAMA Network Open | August 31, 2025 | Volume: 8 | Issue: 8 | Pages: e2529104

10.1001/jamanetworkopen.2025.29104 | PMID 40886088 Get It

Importance Cardiovascular (CV) disease is the leading cause of death globally for both men and women, yet women remain historically underrepresented in CV clinical trials, despite facing a disproportionately high burden of morbidity and mortality in many forms of CV disease. Objective To determine the representation of women across a broad range of CV trials. Evidence Review The participation of women in CV trials registered on ClinicalTrials.gov from 2017 to 2023 was systematically determined through the extraction of publicly available information. Data were extracted to identify the country of study, disease type, trial size, clinical intervention, and age of the participants. The proportion of women and the ratio of number of female to male participants (F:M ratio) were calculated for each trial. The women’s participation:prevalence ratio (PPR) was estimated for each trial based on the relative prevalence of the disease by sex in the specified region. Findings A total of 1079 registered CV trials were identified, including 1 396 104 participants, of whom 571 641 (41.0%) were women. The F:M ratio was significantly lower for studies on arrhythmia (median [IQR], 0.5), coronary heart disease (median [IQR], 0.39 [0.33-0.70]), acute coronary syndrome (median [IQR], 0.32 [0.24-0.51]), and heart failure (median [IQR], 0.51 [0.32-0.87]) but higher for obesity (median [IQR], 1.44 [1.08-4.50]) and pulmonary hypertension (median [IQR], 2.86 [1.50-3.97]) trials. The F:M ratio was higher for trials on lifestyle interventions (median [IQR], 1.51 [0.77-3.24]) than for drug trials. PPRs were low for clinical trials on coronary heart disease (median [IQR], 0.66 [0.50-0.86]), acute coronary syndrome (median [IQR], 0.79 [0.51-0.87]), and stroke (median [IQR], 0.74 [0.61-0.95]). Representation of women in CV trials varied by disease state, region, intervention, and sponsor type. Conclusions and Relevance These findings highlight both progress and persistent challenges in representation of women within CV trials. These gaps not only limit the generalizability of trial outcomes but also perpetuate inequities in evidence-based care for women with CV conditions.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Barnes, Edward L., Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Duricova, Dana, Dubinsky, Marla, Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L., Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

Alimentary Pharmacology & Therapeutics | August 28, 2025 | Volume: 62 | Issue: 11-12 | Pages: 1125-1180

10.1111/apt.70290 | PMID 40874657 Get It

ABSTRACT Background & Aims Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High‐quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results The topics were divided into ten categories with 34 GRADE recommendations and 35 consensus statements. Conclusions Overall, the goal of the group was to provide data‐driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Global Consensus Statement on the Management of Pregnancy in Inflammatory Bowel Disease
Mahadevan, Uma , Seow, Cynthia H. , Flanagan, Emma , Julsgaard, Mette , Kane, Sunanda V. , Watermeyer, Gillian , Fisher, Susan, Anderson, Phil, Ďuricová, Dana , Dubinsky, Marla C. , Long, Millie, IBD, the Global Consensus Group for Pregnancy and, Huang, Vivian , Julsgaard, Mette , Barnes, Edward L. , Chaparro, María , Friedman, Sonia , Ng, Siew C. , Torres, Joana , Yamamoto-Furusho, Jesus , Robinson, Christopher James , Gearry, Richard B. , IBD, the Global Consensus Group for Pregnancy and

Mayo Clinic

American Journal of Gastroenterology | August 27, 2025 | Volume: 121 | Issue: 1 | Pages: 31-79

10.14309/ajg.0000000000003651 | PMID 40862489 Get It

Introduction: Pregnancy can be a complex and risk filled event for women with inflammatory bowel disease (IBD). High-quality studies in this population are lacking, with limited data on medications approved to treat IBD during pregnancy. For patients, limited knowledge surrounding pregnancy impacts pregnancy rates, medication adherence, and outcomes. Limited provider knowledge leads to highly varied practices in care affected by local dogma, available resources, individual interpretation of the literature, and fear of harming the fetus. The variations in guidelines by different societies and countries reflect this and lead to confusion for physicians and patients alike. The Global Consensus Consortium is a group of 39 IBD and content experts and 7 patient advocates from 6 continents who convened to review and assess current data and come to an agreement on best practices based on these data. Methods: The GRADE process was used when sufficient published data were available and the RAND process in those instances where expert opinion was needed to guide consistent practice. Recommendations were informed by the guiding principle that maternal health best supports infant health. Results: The topics were divided into 10 categories with 34 GRADE recommendations and 35 Consensus statements. Discussion: Overall, the goal of the group was to provide data-driven and practical guidance to improve the care of women with IBD around the globe based on the best available research.
Genetic and Cellular Architecture of Breast Cancer Risk Across Ancestries
Zanti, Maria , Williams, Jacob , Jahagirdar, Om , Turcan, Alistair, Brandenburg, Jean‐Tristan , Li, Jingmei, Miranda, Patricio , Godbole, Devika , Zhang, Xiaomeng , Dorling, Leila , Dennis, Joe, John, Esther M. , Kushi, Lawrence H., Carvajal‐Carmona, Luis G. , Haiman, Christopher A. , Ziv, Elad , Easton, Douglas F. , Chanock, Stephen J., Chatterjee, Nilanjan , Kraft, Peter, Wong, Wendy S W , Zhu, Qianqian , Ahearn, Thomas U., Li, Jingmei , Zhang, Haoyu , John, Esther M , Li, Jingmei , Ziv, Elad , Li, James , Jia, Guochong , Hu, Qiang , Li, Yàn , Ho, Weang-Kee , Dias, Julie‐Alexia , Chen, Wenlong Carl , Boddicker, Nicholas , Wang, Ying , Martin, Alicia R. , Zhang, Yan , Torres-Mejı́a, Gabriela , Kushi, Lawrence H, Weitzel, Jeffrey N. , Neuhausen, Susan L. , Fejerman, Laura , Zheng, Wei , Huo, Dezheng , Chanock, Stephen Jacob , Chatterjee, Nilanjan , García‐Closas, Montserrat , Michailidou, Kyriaki , Zhang, Martin Jinye , Dutta, Diptavo , Ahearn, Thomas U.

Mayo Clinic

No container title available | August 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.08.20.25334075 | PMID 40909829 Get It

Abstract Background Breast cancer genome-wide association studies (GWAS) have identified more than 200 susceptibility loci, but most studies are dominated by European and East Asian populations. Methods We analyzed breast cancer GWAS summary statistics from African (AFR), East Asian (EAS), European (EUR), and Hispanic/Latina (H/L) samples (159,297 cases and 212,102 controls). We estimated logit-scale SNP-based heritability, polygenicity, and cross-ancestry genetic correlation, partitioned heritability across functional annotations, and integrated GWAS results with the Tabula Sapiens single-cell atlas using scDRS+. Results The logit-scale heritability of breast cancer ranged from ℎ 2 =0.47 (SE = 0.07) in EAS to AFR ℎ 2 =0.61 (SE = 0.10), with no significant differences across ancestries (p=0.63). The estimated number of susceptibility markers in a sparse normal-mixture effects model also varied from 4,446 (SE = 3,100) in EAS to 8,308 (SE = 2,751) in AFR, but differences were not significant across ancestries (p=0.55). Cross-sample genetic correlations varied, with the strongest correlation between EUR and EAS (𝜌 = 0.79, SE = 0.08) and weakest between AFR and H/L (𝜌 = 0.26, SE = 0.24). Regulatory annotations were enriched for breast cancer heritability across samples. Integration with single-cell expression profiles implicated ancestry-shared associations with innate immune, secretory epithelial, and stromal cell types. Conclusion These results indicate substantial cross-ancestry sharing of breast cancer polygenic architecture, highlight a consistent contribution of regulatory variation, and identify convergent cellular contexts that motivate functional follow-up and inform expectations for the transferability and attainable performance of common-variant risk prediction across populations.
Caregiver experiences after the death of a person with dementia with Lewy bodies: A mixed-methods analysis
Armstrong, Melissa J. , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Sovich, Kaitlin , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M. , Paulson, Henry L. , Fields, Julie A. , Lunde, Angela , Manning, Carol A. , Taylor, Angela , Dai, Yunfeng , LaBarre, Brian , Wang, Tingchang , Jury, Hannah F , Henriquez, Adolfo M , Maixner, Susan M , Lunde, Angela M , Boeve, Brad , Baker, Zachary G , Paulson, Henry L , Armstrong, Melissa J , Wollney, Easton N. , Li, Zhigang , Galvin, James E. , Boeve, Bradley F.

Mayo Clinic

Journal of Alzheimer’s Disease | August 14, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13872877251365218 | PMID 40808538 Get It

Background Dementia with Lewy bodies (DLB) is a common degenerative dementia, but no studies investigate bereaved caregiver experiences. Objective To investigate the experiences of caregivers three months after the death of persons with DLB using a mixed-methods approach. Methods Dyads of individuals with moderate-advanced DLB and their primary informal caregivers were followed prospectively every 6 months until the person with DLB died. Caregivers completed a study visit with questionnaires and a semi-structured interview ∼3 months later. Spearman correlation coefficients and Wilcoxon rank-sum tests evaluated the relationships of post-death measures with pre-death patient and caregiver variables. Thematic analysis was used to analyze the interviews. Results Seventy-three caregivers completed visits (mean 3.5 months post-death). Most of the caregivers were women (82.2%) and spouses (76.7%) or adult children (17.8%). Over 40% had scores indicating risk for clinical depression. Post-death caregiver experiences (depression, quality of life, grief, resilience) correlated with pre-death caregiver experiences. Post-death experiences did not associate with patient characteristics, disease-related symptoms, or healthcare services used in the last 6 months of life. Trajectories for caregiver measures from pre- to post-death visits varied widely. Interview themes included grief and sadness, anger, guilt and regret, relief, appreciation/gratitude, and adjusting to a new normal. Conclusions The finding that pre-death caregiving experiences have the strongest association with post-death experiences emphasizes the critical importance of accessible and evidence-based caregiver support before and after the death of a person with DLB. Research is needed to develop interventions for current and bereaved caregivers of individuals with DLB. Trial registration information NCT04829656 (submitted 2021-03-22).
Antipsychotic Use in Bipolar Disorder: Clinical and Genomic Correlates– A Mayo Clinic Bipolar Disorder Biobank Study
Bond, David J. , Pendegraft, Richard S., Batzler, Anthony , Gardea-Reséndez, Manuel, Prieto, Miguel L. , Frye, Mark A. , Bond, David J , Singh, Balwinder , Ho, Ada Man‐Choi , Coombes, Brandon J. , Romo‐Nava, Francisco , Veldić, Marin , Cuéllar‐Barboza, Alfredo B. , Gardea‐Resendez, Manuel , Özerdem, Ayşegül , McElroy, Susan L. , Biernacka, Joanna M.

Mayo Clinic

No container title available | August 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7274612/v1 | PMID 40799747 Get It

Abstract Background: Responsiveness to mood-stabilizing pharmacotherapy varies in bipolar disorder (BD). We investigated clinical correlates of second-generation antipsychotic (SGA) treatment response and conducted the first genome-wide association study (GWAS), including exploratory polygenic scores (PGS), of SGA pharmacogenomic treatment response in BD. Methods: Treatment response was quantified using the Alda scale, and GWAS was performed using Alda-A score, controlling for sex, genotyping batch, and the genomic principal components. Results: The cohort included 2,159 adults with BD (1,416 BD-I, 691 BD-II, 51 schizoaffective BD), mean age 41.8 years, 62% female, 84% white, and 14% Hispanic. Nearly half (48%) were treated with SGAs. Current SGA users were younger (41.2±14.7 vs. 42.5±15.3 years, p =0.040), more likely to be Hispanic (14% vs. 11%, p =0.047), had a higher body mass index (BMI; 30.4±7.6 vs. 29.5±7.1 kg/m 2 , p =0.005). Lifetime comorbidity patterns for current SGA users include higher rates of manic psychosis (29% vs. 17%, p <0.001) and eating disorders — Anorexia Nervosa (7% vs. 4%, p =0.003), Bulimia Nervosa (7% vs. 4%, p =0.003), and Binge Eating Disorder (14% vs. 11%, p =0.030). We detected a genome-wide significant association between SGA Alda-A scores and GAS7 variants (top variant: rs202127418, β =-2.998, p =4.96E-08). However, SGA response was not significantly associated with PGS for schizophrenia, BD, and major depression (FDR>0.05). Conclusions: SGAs are frequently utilized as mood stabilizers in patients with BD and are associated with manic psychosis and eating disorders. GAS7 variants may predict SGA response, but larger, more diverse cohorts are needed for validation.
Wilms Tumor, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benedetti, Daniel J. , Brown, Brandon , Cook, Shelly, Desai, Ami V. , Fair, Douglas , Hiniker, Susan M. , Jasty‐Rao, Rama, Just, Marissa, Kieran, Kathleen , Lin, Chi , MacEwan, Iain, Martínez-Agosto, Julián A. , Mullen, Elizabeth A. , Murphy, Erin S. , Ranalli, Mark , Rhee, Daniel S. , Wickiser, Jonathan E., Yoon, Janet, Zapala, Matthew A. , Sliker, Bailee , Horst, Kelly , Balis, Frank M. , Green, Daniel M. , Armstrong, Amy J. , Aye, Jamie M. , Brown, Brandon Douglas , Brown, Erin G. , Dhillon, Jasreman , Geynisman, Daniel M. , Horst, Kelly K. , Pinto, Navin , Rokitka, Denise A. , Walz, Amy L. , Montgomery, Sarah E.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | August 5, 2025 | Volume: 23 | Issue: 8 | Pages: 319-342

10.6004/jnccn.2025.0037 | PMID 40763792 Get It

The NCCN Clinical Practice Guidelines (NCCN Guidelines) for Wilms Tumor (WT; nephroblastoma) cover strategies for the screening, diagnosis, and treatment of WT, which is the most frequent primary kidney tumor in children. WT can generally be separated into 2 histology types: favorable histology WT and anaplastic WT. Five-year survival is high for children with favorable histology WT who receive appropriate treatment; however, survival rates are much lower for patients who present with higher stage diffuse anaplastic WT. Treatment of WT can range from surgery alone to surgery plus intensive chemotherapy and radiation depending on whether the tumor is unilateral or bilateral, histology, and local stage. The goal of therapy is to maximize cure while minimizing long-term toxicities. The content featured in this issue covers the NCCN panel’s recommendations for overall management of both favorable histology WT and anaplastic WT.